Pooled analysis of data from phase I and II studies used to evaluate AE of interstitial lung disease\/pneumonitis associated with T-Dxd<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n MONDAY, Aug. 22, 2022 (HealthDay News) — For patients receiving trastuzumab deruxtecan (T-DXd) monotherapy, the incidence of adjudicated drug-related interstitial lung disease (ILD)\/pneumonitis is 15.4 percent, according to a study published online Aug. 11 in ESMO Open<\/em>.\n<\/p>\n \n\tCharles A. Powell, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a pooled analysis of nine phase I and II T-DXd monotherapy studies to describe drug-related ILD\/pneumonitis. A total of 1,150 patients (44.3, 25.6, 17.7, 9.3, and 3.0 percent with breast, gastric, lung, colorectal, and other cancer, respectively) were included in the analysis (median treatment duration, 5.8 months; median of four prior lines of therapy).\n<\/p>\n \n\tThe researchers found that the incidence of adjudicated drug-related ILD\/pneumonitis was 15.4 percent overall (grade 5, 2.2 percent); a majority of patients experienced low-grade events (grade 1 or 2, 77.4 percent). Most patients (87.0 percent) had their first event within 12 months of the first dose of T-DXd (median, 5.4 months). For 53.2 percent of events, adjudicated ILD\/pneumonitis onset occurred earlier than identified by investigators (median difference in onset, 43 days). Baseline factors potentially associated with an increased risk for adjudicated drug-related ILD\/pneumonitis included age younger than 65 years, enrollment in Japan, T-DXd dose >6.4 mg\/kg, oxygen saturation <95 percent, moderate\/severe renal impairment, lung comorbidities, and more than four years since the initial diagnosis.\n<\/p>\n \n\t“The monitoring, diagnosis, and management of ILD\/pneumonitis is an area of continuing improvement; to this end, new toxicity guidelines have been implemented, and education has been provided to health care providers and patients,” the authors write.\n<\/p>\n \n\tSeveral authors disclosed ties to pharmaceutical companies, including AstraZeneca and Daiichi Sankyo, which developed and commercialized T-DXd and funded the study.\n<\/p>\n